Published on 25 Apr 2013
Sign up for Email Alerts and keep in touch with Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine journal news, updates, events and articles
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
PDF (700.86 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
This was the most efficient and user-friendly publishing process I have experienced. The editorial team at Libertas Academica was phenomenal. They kept me engaged with each step of the publishing process and they were timely and professional with their response to my inquiries. I look forward to publishing additional articles with Libertas Academica in the future.